The news reported by BW Healthcare World, announcing Mahajan Imaging's introduction of an AI-integrated blood biomarker test for the early diagnosis of Alzheimer's, reflects a rapidly advancing area in global healthcare. Mahajan Imaging & Labs is a well-established and innovative diagnostic chain in India, known for integrating advanced technologies like Artificial Intelligence into its various diagnostic services, including MRI and CT scanning, as evidenced by their past introductions of AI-powered MRI centers and advanced CT scanners. This background makes the claim of their involvement in AI-driven blood tests for Alzheimer's plausible within the context of their operational focus. Globally, the development of AI-integrated blood biomarker tests for early Alzheimer's disease detection is a major breakthrough. Several reports highlight new blood tests capable of identifying key biomarkers, such as amyloid plaques and tau proteins, with high accuracy for early diagnosis. The U.S. FDA has approved such blood tests in recent times, signaling a shift towards less invasive and more accessible diagnostic methods. Experts widely regard these blood tests as a 'game-changer' for their potential to revolutionize Alzheimer's diagnosis and treatment by providing simpler, more cost-effective alternatives to traditional methods like PET scans or spinal taps. Despite the contextual credibility of the news, extensive real-time Google searches for the specific article titled 'Mahajan Imaging Introduces AI Integrated Blood Biomarker Test For Early Alzheimer's Diagnosis - BW Healthcare World' did not yield the original article or its publication date. Consequently, while the underlying technological capabilities and Mahajan Imaging's innovative standing are corroborated, the precise details and the specific announcement from the cited source could not be independently verified. Therefore, the factual status of this particular news item remains unconfirmed from the provided source.